Tactile Systems Technology, Inc. (TCMD)

In the past six months, Tactile Systems Technology, Inc. (TCMD) stock price has seen a significant increase of approximately 199.90%. Over the past year, the stock price increased by 73.66%. Key events impacting the stock include the Q3 2025 earnings report where the company reported EPS of $0.36, surpassing estimates, and revenue of $85.76 million, also exceeding estimates. Analyst rating changes occurred, with Lake Street Capital boosting its price objective to $32.00 and issuing a "buy" rating, and Wall Street Zen upgrading the stock to "strong-buy". Zacks Research downgraded TCMD from a "strong-buy" to a "hold" rating. Raymond James Financial and Piper Sandler both set a $35.00 price target in January 2026. The company's stock dropped in February 2024 due to light Q4 revenue and underwhelming forward guidance. Management raised its full-year 2025 total revenue guidance to a range of $317 million to $321 million, representing approximately 8% to 10% year-over-year growth.

The provided information does not explicitly detail specific demand seasonality for Tactile Systems Technology, Inc.'s products and services. General trends indicate that shifts toward at-home care and improved reimbursement policies are increasing demand for the company's offerings. The company's focus on chronic conditions suggests a more consistent demand driven by ongoing patient needs rather than pronounced seasonal fluctuations.

Tactile Systems Technology, Inc., also known as Tactile Medical, operates in the Healthcare sector, specifically the Medical Equipment & Supplies industry. The company specializes in non-invasive, at-home therapeutic solutions for chronic conditions, including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease. Its major products include the Flexitouch® Plus System, a pneumatic compression device for lymphedema treatment; the Entre™ System, a portable pneumatic compression device for chronic venous insufficiency and lymphedema; the AffloVest®, a portable high-frequency chest wall oscillation vest for airway clearance; the Nimbl™ platform, a next-generation pneumatic compression platform; and Kylee, a free mobile application designed to help patients learn about lymphedema.

Tactile Systems Technology, Inc. is headquartered in Minneapolis, Minnesota, USA. The company primarily develops, manufactures, and distributes its medical devices to customers within the United States.

Tactile Systems Technology maintains a strong brand and reputation, particularly as a market leader in the lymphedema treatment market. The company is recognized for its innovative medical devices and its focus on at-home therapy solutions for chronic diseases. There is no explicit information detailing specific events that have negatively affected Tactile Systems Technology, Inc.'s brand reputation in the past year, beyond what might be inferred from stock performance or analyst sentiment.

Tactile Systems Technology, Inc. has substantial institutional ownership, with 295 institutional owners and shareholders holding a total of 23,109,556 shares, accounting for 83.43% of the stock. Major institutional owners include Morgan Stanley, Cadian Capital Management, Lp, BlackRock, Inc., Vanguard Group Inc, Paradigm Capital Management Inc/Ny, Dimensional Fund Advisors Lp, Capitolis Liquid Global Markets LLC, and Acadian Asset Management Llc. Insider sentiment for TCMD is negative, primarily due to significant open-market selling by key executives, outweighing lower-impact acquisitions like stock awards. Insiders hold 2.50% of the stock.